CAS 1398583-31-7

Formule : C26H21FN2O3

InChI : InChI=1S/C26H21FN2O3/c1-17(19-9-11-23(27)12-10-19)29(16-18-5-4-7-21(13-18)26(31)32)25(30)22-14-20-6-2-3-8-24(20)28-15-22/h2-15,17H,16H2,1H3,(H,31,32)/t17-/m1/s1

Code InChI : BXNMZRPTQFVRFA-QGZVFWFLSA-N

SMILES : C[C@H](C1=CC=C(C=C1)F)N(CC2=CC(=CC=C2)C(=O)O)C(=O)C3=CC4=CC=CC=C4N=C3

(R)-3-((N-(1-(4-Fluorophenyl)ethyl)quinoline-3-carboxamido)methyl)benzoic acid

CAS : 1398583-31-7

Formule : C₂₆H₂₁FN₂O₃

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 428.4549

Ref: IN-DA01ENKI

PF-05105679

CAS : 1398583-31-7

PF-05105679

Formule : C₂₆H₂₁FN₂O₃

Degré de pureté : ≥98%

Masse moléculaire : 428.45

Ref: 54-BUP12884

PF 05105679

CAS : 1398583-31-7

PF 05105679 is an investigational pharmaceutical compound developed by Pfizer, classified as a selective nicotinic acetylcholine receptor (nAChR) antagonist. It is synthesized through meticulous organic chemistry techniques, representing a targeted approach to modifying neural pathways. The compound functions by selectively inhibiting specific subtypes of nAChRs, which are ligand-gated ion channels integral to synaptic transmission and neurophysiological processes.

Formule : C₂₆H₂₁FN₂O₃

Degré de pureté : Min. 95%

Masse moléculaire : 428.45 g/mol

Ref: 3D-YFC58331

PF-05105679

CAS : 1398583-31-7

PF-05105679 is a selective TRPM8 antagonist (IC50 = 103 nM). PF-05105679 can be used in research on cold-related pain.

Formule : C₂₆H₂₁FN₂O₃

Degré de pureté : 99.84%

Couleur et forme : Solid

Masse moléculaire : 428.45

Ref: TM-T16483